Brought to you by 
Juno pays $42mm in cash and stock to buy X-BODY
29 Sep 2020
Executive Summary
Private antibody engineering company X-BODY Inc. was acquired by Juno Therapeutics Inc. Juno paid $21mm in cash, issued 439k of its shares (valued at $21mm), and could hand over earn-outs for R&D, regulatory, and sales achievements.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Juno pays $42mm in cash and stock to buy X-BODY
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice